ABOUT THE DISORDER
Is a chronic progressive non-scarring alopecia. It typically presents as a diffuse hair loss in the mid and frontal regions of the scalp with preservation of the frontal hairline. It is the most common hair loss disorder affecting all women. The exact cause of FPHL is unknown and is likely multifactorial and may include genetic predisposition, follicular androgen sensitivity, and micro-inflammation. Management includes anti-androgen (i.e spironolactone, finasteride), minoxidil (oral/ topical), low-level light therapy, platelet rich plasma, scalp camouflage (i.e. scalp micropigmentation, hair fibers, wigs), essential oils (i.e rosemary), and nutritional supplementation.
– Panahi Y. et al.. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: A randomized comparative trial. Skinmed. 2015;13(1):15-2
– Redler S. et al. Genetics and other factors in the aetiology of female pattern hair loss. Exp Dermatol. 2017 Jun;26(6):510-51
– Farris PK et al.. A Novel Multi-Targeting Approach to Treating Hair Loss, Using Standardized Nutraceuticals. J Drugs Dermatol. 2017 Nov 1;16(11):s141-s148
– Kanti V, et al. . Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):11-22.